Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 27, 2022 (4 years ago)

HYDROCORTISONE 9a) 2MG IN NS 0.2ML SYRINGE

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of sterility assurance

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

HYDROCORTISONE 9a) 2MG IN NS 0.2ML SYRINGE, 9MG IN NS 2ML SYRINGE, steroid, Rx Only, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320, NDC# 00009-0011-04

Affected NDC 0009-0011-04

Compare with the code on your package — it is the most precise check available.

Drug: Hydrocortisone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Solu-Cortef
hydrocortisone sodium succinate
NDC 00009-0011
100 mg/2mL Injection, Powder, for Solution
Intramuscular|intravenous
Pharmacia & Upjohn Company LLC Rx
Recalling firm
Sentara Infusion Services
NDC code
00009-0011-04
Origin
VA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0295-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrocortisone recalls

See all
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0640-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0639-2026
Class III · Low risk

Skin Rehab

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-04 D-0481-2026
Class III · Low risk

Remedy Gel

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-12 D-0480-2026

Other recalls by Sentara Infusion Services

All 2022 recalls